27 results on '"Wood, DA"'
Search Results
2. Transcatheter aortic valve implantation: durability of clinical and hemodynamic outcomes beyond 3 years in a large patient cohort.
- Author
-
Gurvitch R, Wood DA, Tay EL, Leipsic J, Ye J, Lichtenstein SV, Thompson CR, Carere RG, Wijesinghe N, Nietlispach F, Boone RH, Lauck S, Cheung A, and Webb JG
- Published
- 2010
- Full Text
- View/download PDF
3. Principles for national and regional guidelines on cardiovascular disease prevention: a scientific statement from the World Heart and Stroke Forum.
- Author
-
Smith SC Jr., Jackson R, Pearson TA, Fuster V, Yusuf S, Faergeman O, Wood DA, Alderman M, Horgan J, Home P, Hunn M, Grundy SM, and World Heart and Stroke Forum
- Published
- 2004
4. Platypnea-Orthodeoxia Syndrome After Esophageal Dilation in a Patient With a Dilated Ascending Aorta.
- Author
-
Saunders MB, Michaleski MS, Yim J, Marchand M, Jue J, Wood DA, Luong CL, Tsang MYC, Tsang TSM, and Yeung DF
- Published
- 2024
- Full Text
- View/download PDF
5. Complete Revascularization Versus Culprit-Lesion-Only PCI in STEMI Patients With Diabetes and Multivessel Coronary Artery Disease: Results From the COMPLETE Trial.
- Author
-
Oqab Z, Kunadian V, Wood DA, Storey RF, Rao SV, Mehran R, Pinilla-Echeverri N, Mani T, Boone RH, Kassam S, Bossard M, Mansour S, Ball W, Sibbald M, Valettas N, Moreno R, Steg PG, Cairns JA, and Mehta SR
- Subjects
- Humans, Treatment Outcome, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease therapy, Diabetes Mellitus diagnosis, Myocardial Infarction therapy, Percutaneous Coronary Intervention adverse effects, ST Elevation Myocardial Infarction diagnostic imaging, ST Elevation Myocardial Infarction therapy
- Abstract
Background: In the COMPLETE trial (Complete Versus Culprit-Only Revascularization to Treat Multivessel Disease After Early PCI for STEMI), a strategy of complete revascularization reduced the risk of major cardiovascular events compared with culprit-lesion-only percutaneous coronary intervention in patients presenting with ST-segment-elevation myocardial infarction (STEMI) and multivessel coronary artery disease. Patients with diabetes have a worse prognosis following STEMI. We evaluated the consistency of the effects of complete revascularization in patients with and without diabetes., Methods: The COMPLETE trial randomized a strategy of complete revascularization, consisting of angiography-guided percutaneous coronary intervention of all suitable nonculprit lesions, versus a strategy of culprit-lesion-only percutaneous coronary intervention (guideline-directed medical therapy alone). In prespecified analyses, treatment effects were determined in patients with and without diabetes on the first coprimary outcome of cardiovascular death or new myocardial infarction and the second coprimary outcome of cardiovascular death, new myocardial infarction, or ischemia-driven revascularization. Interaction P values were calculated to evaluate whether there was a differential treatment effect in patients with and without diabetes., Results: Of the 4041 patients enrolled in the COMPLETE trial, 787 patients (19.5%) had diabetes. The median HbA1c (glycated hemoglobin) was 7.7% in the diabetes group and 5.7% in the nondiabetes group. Complete revascularization consistently reduced the first coprimary outcome in patients with diabetes (hazard ratio, 0.87 [95% CI, 0.59-1.29]) and without diabetes (hazard ratio, 0.70 [95% CI, 0.55-0.90]), with no evidence of a differential treatment effect (interaction P =0.36). Similarly, for the second coprimary outcome, no differential treatment effect (interaction P =0.27) of complete revascularization was found in patients with diabetes (hazard ratio, 0.61 [95% CI, 0.43-0.87]) and without diabetes (hazard ratio, 0.48 [95% CI, 0.39-0.60])., Conclusions: Among patients presenting with STEMI and multivessel disease, the benefit of complete revascularization over a culprit-lesion-only percutaneous coronary intervention strategy was consistent regardless of the presence or absence of diabetes., Competing Interests: Disclosures Dr Mehta reports grants from Canadian Institute of Health Research, grants from AstraZeneca and Boston Scientific, during the conduct of the study. Dr Mehran reports grants and other from Abbott, grants and other from Abiomed, grants and other from Applied Therapeutics, grants and other from Arena, grants from AstraZeneca, grants and other from Bayer, grants and other from Biosensors, grants, personal fees and other from Boston Scientific, grants and other from CardiaWave, grants from CellAegis, grants from CERC, grants and other from Chiesi, grants and other from Concept Medical, grants and other from CSL Behring, grants and other from DSI, grants from Insel Gruppe AG, grants and other from Medtronic, other from Novartis, grants from OrbusNeich, grants and other from Philips, grants from Transverse Medical, grants from Zoll, personal fees from California Institute for Regenerative Medicine (CIRM), personal fees from Cine-Med Research, personal fees from Janssen, personal fees from WebMD, personal fees from SCAI, other from AM Pharma, other from Alleviant Medical, other from CeloNova BioSciences, other from Duke University, other from Humacyte, from Idorsia Pharmaceuticals, personal fees from AMA, other from Biotronik, other from Elixir Medical, other from STEL, other from ControlRad, other from CRF, other from ACC, outside the submitted work. Dr Storey reports personal fees from Bayer, personal fees from Bristol-Myers Squibb/Pfizer, grants and personal fees from AstraZeneca, grants and personal fees from Thromboserin, grants and personal fees from Glycardial Diagnostics, personal fees from Portola, personal fees from Medscape, grants and personal fees from Cytosorbents, personal fees from Intas Pharmaceuticals, personal fees from Hengrui, personal fees from Sanofi Aventis, personal fees from Idorsia, personal fees from PhaseBio, personal fees from Alnylam, personal fees from CSL-Behring, personal fees from Novartis, personal fees from Chiesi, outside the submitted work. Dr Pinilla-Echeverri reports grants from Boston Scientific, grants from AstraZeneca, grants from Canadian Institutes of Health Research, grants from Population Health Research Institute, during the conduct of the study; personal fees from Abbott, personal fees from Philips, personal fees from Conavi, personal fees from Novartis, outside the submitted work. Dr Moreno reports other from Abbott Vascular, other from Boston Scientific, other from Biosensors, other from Biotronik, other from Medtronic Inc., other from Daiichi-Sankyo, other from AMGEN, other from AstraZeneca, other from Edwards Lifesciences, other from Terumo, other from Philips, other from Cardinal Health, outside the submitted work. Dr Steg reports grants and personal fees from Amarin, personal fees from Amgen, personal fees and nonfinancial support from AstraZeneca, grants and personal fees from Bayer, personal fees from Bristol-Myers Squibb, personal fees from Boehringer Ingelheim, personal fees from Idorsia, personal fees from Novartis, personal fees from Novo Nordisk, personal fees from Pfizer, personal fees from Sanofi/Lexicon, grants and personal fees from Servier, personal fees from Myokardia, grants and personal fees from Sanofi, personal fees from Regeneron, personal fees from Phase Bio, outside the submitted work. Dr Cairns reports grants from Boston Scientific, grants from Astra Zeneca, grants from CIHR, during the conduct of the study; personal fees from Abbott, personal fees from Bayer, personal fees from BMS Pfizer, outside the submitted work. Dr Sibbald reports grants from Abbott Vascular and Phillips. The remainder of authors have nothing to disclose.
- Published
- 2023
- Full Text
- View/download PDF
6. Economics of Minimalist Transcatheter Aortic Valve Replacement: Results From the 3M-TAVR Economic Study.
- Author
-
Butala NM, Wood DA, Li H, Chinnakondepalli K, Lauck SB, Sathananthan J, Cairns JA, Magnuson EA, Barker M, Webb JG, Welsh R, Cheung A, Ye J, Velianou JL, Wijeysundera HC, Asgar A, Kodali S, Thourani VH, and Cohen DJ
- Subjects
- Aged, Aged, 80 and over, Humans, Medicare economics, Risk Factors, Treatment Outcome, United States, Aortic Valve Stenosis surgery, Transcatheter Aortic Valve Replacement adverse effects, Transcatheter Aortic Valve Replacement methods
- Abstract
Background: The 3M-TAVR trial (3M-Transcatheter Aortic Valve Replacement) demonstrated the feasibility and safety of next-day hospital discharge after transfemoral TAVR with implementation of a minimalist pathway. However, the economic impact of this approach is unknown. Therefore, we evaluated costs for patients undergoing minimalist TAVR compared with conventional TAVR., Methods: We used propensity matching to compare resource utilization and costs (from a US health care system perspective) for patients in the 3M-TAVR trial with those for transfemoral TAVR patients enrolled in the contemporaneous S3i trial (PARTNER SAPIEN-3 Intermediate Risk). Procedural costs were estimated using measured resource utilization for both groups. For the S3i group, all other costs through 30-day follow-up were assessed by linkage with Medicare claims; for 3M, these costs were assessed using regression models derived from S3i cost and resource utilization data., Results: After 1:1 propensity matching, 351 pairs were included in our study (mean age 82, mean Society of Thoracic Surgery risk score 5.3%). There were no differences in death, stroke, or rehospitalization between the 3M-TAVR and S3i groups through 30-day follow-up. Index hospitalization costs were $10 843/patient lower in the 3M-TAVR cohort, driven by reductions in procedure duration, anesthesia costs, and length of stay. Between discharge and 30 days, costs were similar for the 2 groups such that cumulative 30-day costs were $11 305/patient lower in the 3M-TAVR cohort compared with the S3i cohort ($49 425 versus $60 729, 95% CI for difference $9378 to $13 138; P <0.001)., Conclusions: Compared with conventional transfemoral TAVR, use of a minimalist pathway in intermediate-risk patients was associated with similar clinical outcomes and substantial in-hospital cost savings, which were sustained through 30 days., Registration: URL: https://www., Clinicaltrials: gov; Unique identifier: NCT02287662.
- Published
- 2022
- Full Text
- View/download PDF
7. Standardized Invasive Hemodynamics for Management of Patients With Elevated Echocardiographic Gradients Post-Transcatheter Aortic Valve Replacement at Midterm Follow-Up.
- Author
-
Barker M, Abbas AE, Webb JG, Pibarot P, Sathananthan J, Brunner N, Wang DD, Wang J, Leon MB, and Wood DA
- Subjects
- Aortic Valve diagnostic imaging, Aortic Valve surgery, Echocardiography, Follow-Up Studies, Hemodynamics, Humans, Prosthesis Design, Treatment Outcome, Aortic Valve Stenosis diagnostic imaging, Aortic Valve Stenosis surgery, Heart Valve Prosthesis, Transcatheter Aortic Valve Replacement adverse effects
- Published
- 2022
- Full Text
- View/download PDF
8. Complete Revascularization in Patients Undergoing a Pharmacoinvasive Strategy for ST-Segment-Elevation Myocardial Infarction: Insights From the COMPLETE Trial.
- Author
-
Dehghani P, Cantor WJ, Wang J, Wood DA, Storey RF, Mehran R, Bainey KR, Welsh RC, Rodés-Cabau J, Rao S, Lavi S, Velianou JL, Natarajan MK, Ziakas A, Guiducci V, Fernández-Avilés F, Cairns JA, and Mehta SR
- Subjects
- Humans, Myocardial Revascularization, Thrombolytic Therapy, Treatment Outcome, Percutaneous Coronary Intervention adverse effects, ST Elevation Myocardial Infarction diagnostic imaging, ST Elevation Myocardial Infarction surgery
- Abstract
[Figure: see text].
- Published
- 2021
- Full Text
- View/download PDF
9. Nonculprit Lesion Plaque Morphology in Patients With ST-Segment-Elevation Myocardial Infarction: Results From the COMPLETE Trial Optical Coherence Tomography Substudys.
- Author
-
Pinilla-Echeverri N, Mehta SR, Wang J, Lavi S, Schampaert E, Cantor WJ, Bainey KR, Welsh RC, Kassam S, Mehran R, Storey RF, Nguyen H, Meeks B, Wood DA, Cairns JA, and Sheth T
- Subjects
- Aged, Canada epidemiology, Coronary Artery Disease epidemiology, Coronary Artery Disease therapy, Female, Fibrosis, Humans, Male, Middle Aged, Percutaneous Coronary Intervention, Predictive Value of Tests, Prevalence, Prospective Studies, Randomized Controlled Trials as Topic, ST Elevation Myocardial Infarction epidemiology, ST Elevation Myocardial Infarction therapy, Coronary Artery Disease diagnostic imaging, Coronary Vessels diagnostic imaging, Plaque, Atherosclerotic, ST Elevation Myocardial Infarction diagnostic imaging, Tomography, Optical Coherence
- Abstract
Background: Complete revascularization with routine percutaneous coronary intervention of nonculprit lesions after primary percutaneous coronary intervention improves outcomes in ST-segment-elevation myocardial infarction. Whether this benefit is associated with nonculprit lesion vulnerability is unknown., Methods: In a prospective substudy of the COMPLETEs trial (Complete vs Culprit-Only Revascularization to Treat Multi-Vessel Disease After Early PCI for STEMI), we performed optical coherence tomography of at least 2 coronary arteries before nonculprit lesion percutaneous coronary intervention in 93 patients with ST-segment-elevation myocardial infarction and multivessel disease; and the ST-segment-elevation myocardial infarction culprit vessel if there was unstented segment amenable to imaging. Nonculprit lesions were categorized as obstructive (≥70% stenosis by visual angiographic assessment) or nonobstructive, and as thin-cap fibroatheroma (TCFA) or non-TCFA by optical coherence tomography criteria. TCFA was defined as a lesion with mean fibrous cap thickness <65 μm overlying a lipid arc >90°., Results: On a patient level, at least one obstructive TCFA was observed in 44/93 (47%) of patients. On a lesion level, there were 58 TCFAs among 150 obstructive nonculprit lesions compared with 74 TCFAs among 275 nonculprit lesions (adjusted TCFA prevalence: 35.4% versus 23.2%, P =0.022). Compared with obstructive non-TCFAs, obstructive TCFAs had similar lesion length (23.1 versus 20.8 mm, P =0.16) but higher lipid quadrants (55.2 versus 19.2, P <0.001), greater mean lipid arc (203.8° versus 84.5°, P <0.001), and more macrophages (97.1% versus 54.4%, P <0.001) and cholesterol crystals (85.8% versus 44.3%, P <0.001). For nonobstructive lesions, TCFA lesions had similar lesion length (16.7 versus 14.6 mm, P =0.11), but more lipid quadrants (36.4 versus 13.5, P <0.001), and greater mean lipid arc (191.8° versus 84.2°, P <0.001) compared with non-TCFA., Conclusions: Among patients who underwent optical coherence tomography imaging in the COMPLETE trial, nearly 50% had at least one obstructive nonculprit lesion containing complex vulnerable plaque. Obstructive lesions more commonly harbored vulnerable plaque morphology than nonobstructive lesions. This may help explain the benefit of routine percutaneous coronary intervention of obstructive nonculprit lesions in patients with ST-segment-elevation myocardial infarction and multivessel disease. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01740479s.
- Published
- 2020
- Full Text
- View/download PDF
10. Pivotal Clinical Study to Evaluate the Safety and Effectiveness of the MANTA Percutaneous Vascular Closure Device.
- Author
-
Wood DA, Krajcer Z, Sathananthan J, Strickman N, Metzger C, Fearon W, Aziz M, Satler LF, Waksman R, Eng M, Kapadia S, Greenbaum A, Szerlip M, Heimansohn D, Sampson A, Coady P, Rodriguez R, Krishnaswamy A, Lee JT, Ben-Dor I, Moainie S, Kodali S, Chhatriwalla AK, Yadav P, O'Neill B, Kozak M, Bacharach JM, Feldman T, Guerrero M, Nanjundappa A, Bersin R, Zhang M, Potluri S, Barker C, Bernardo N, Lumsden A, Barleben A, Campbell J, Cohen DJ, Dake M, Brown D, Maor N, Nardone S, Lauck S, O'Neill WW, and Webb JG
- Subjects
- Aged, Aged, 80 and over, Equipment Design, Female, Hemorrhage etiology, Hemostatic Techniques adverse effects, Humans, Male, North America, Prospective Studies, Punctures, Risk Factors, Time Factors, Treatment Outcome, Catheterization, Peripheral adverse effects, Endovascular Procedures adverse effects, Hemorrhage prevention & control, Hemostatic Techniques instrumentation, Transcatheter Aortic Valve Replacement adverse effects, Vascular Closure Devices adverse effects
- Abstract
Background: Open surgical closure and small-bore suture-based preclosure devices have limitations when used for transcatheter aortic valve replacement, percutaneous endovascular abdominal aortic aneurysm repair, or percutaneous thoracic endovascular aortic aneurysm repair. The MANTA vascular closure device is a novel collagen-based technology designed to close large bore arteriotomies created by devices with an outer diameter ranging from 12F to 25F. In this study, we determined the safety and effectiveness of the MANTA vascular closure device., Methods and Results: A prospective, single arm, multicenter investigation in patients undergoing transcatheter aortic valve replacement, percutaneous endovascular abdominal aortic aneurysm repair, or thoracic endovascular aortic aneurysm repair at 20 sites in North America. The primary outcome was time to hemostasis. The primary safety outcomes were accessed site-related vascular injury or bleeding complications. A total of 341 patients, 78 roll-in, and 263 in the primary analysis cohort, were entered in the study between November 2016 and September 2017. For the primary analysis cohort, transcatheter aortic valve replacement was performed in 210 (79.8%), and percutaneous endovascular abdominal aortic aneurysm repair or thoracic endovascular aortic aneurysm repair was performed in 53 (20.2%). The 14F MANTA was used in 42 cases (16%), and the 18F was used in 221 cases(84%). The mean effective sheath outer diameter was 22F (7.3 mm). The mean time to hemostasis was 65±157 seconds with a median time to hemostasis of 24 seconds. Technical success was achieved in 257 (97.7%) patients, and a single device was deployed in 262 (99.6%) of cases. Valve Academic Research Consortium-2 major vascular complications occurred in 11 (4.2%) cases: 4 received a covered stent (1.5%), 3 had access site bleeding (1.1%), 2 underwent surgical repair (0.8%), and 2 underwent balloon inflation (0.8%)., Conclusions: In a selected population, this study demonstrated that the MANTA percutaneous vascular closure device can safely and effectively close large bore arteriotomies created by current generation transcatheter aortic valve replacement, percutaneous endovascular abdominal aortic aneurysm repair, and thoracic endovascular aortic aneurysm repair devices., Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT02908880.
- Published
- 2019
- Full Text
- View/download PDF
11. Multivessel Revascularization and ST-Segment-Elevation Myocardial Infarction: Do We Have the Complete Answer?
- Author
-
Wood DA, Cairns JA, and Mehta SR
- Subjects
- Humans, Prognosis, Percutaneous Coronary Intervention, ST Elevation Myocardial Infarction
- Published
- 2017
- Full Text
- View/download PDF
12. The Heart of 25 by 25: Achieving the Goal of Reducing Global and Regional Premature Deaths From Cardiovascular Diseases and Stroke: A Modeling Study From the American Heart Association and World Heart Federation.
- Author
-
Sacco RL, Roth GA, Reddy KS, Arnett DK, Bonita R, Gaziano TA, Heidenreich PA, Huffman MD, Mayosi BM, Mendis S, Murray CJ, Perel P, Piñeiro DJ, Smith SC Jr, Taubert KA, Wood DA, Zhao D, and Zoghbi WA
- Subjects
- Adult, Age Factors, Aged, Cardiovascular Diseases diagnosis, Cause of Death, Female, Humans, Interdisciplinary Communication, Intersectoral Collaboration, Male, Middle Aged, Prognosis, Risk Assessment, Risk Factors, Stroke diagnosis, Time Factors, United States, American Heart Association, Cardiology trends, Cardiovascular Diseases mortality, Cardiovascular Diseases therapy, Global Health trends, Models, Cardiovascular, Stroke mortality, Stroke therapy
- Abstract
In 2011, the United Nations set key targets to reach by 2025 to reduce the risk of premature noncommunicable disease death by 25% by 2025. With cardiovascular disease being the largest contributor to global mortality, accounting for nearly half of the 36 million annual noncommunicable disease deaths, achieving the 2025 goal requires that cardiovascular disease and its risk factors be aggressively addressed. The Global Cardiovascular Disease Taskforce, comprising the World Heart Federation, American Heart Association, American College of Cardiology Foundation, European Heart Network, and European Society of Cardiology, with expanded representation from Asia, Africa, and Latin America, along with global cardiovascular disease experts, disseminates information and approaches to reach the United Nations 2025 targets. The writing committee, which reflects Global Cardiovascular Disease Taskforce membership, engaged the Institute for Health Metrics and Evaluation, University of Washington, to develop region-specific estimates of premature cardiovascular mortality in 2025 based on various scenarios. Results show that >5 million premature CVD deaths among men and 2.8 million among women are projected worldwide by 2025, which can be reduced to 3.5 million and 2.2 million, respectively, if risk factor targets for blood pressure, tobacco use, diabetes mellitus, and obesity are achieved. However, global risk factor targets have various effects, depending on region. For most regions, United Nations targets for reducing systolic blood pressure and tobacco use have more substantial effects on future scenarios compared with maintaining current levels of body mass index and fasting plasma glucose. However, preventing increases in body mass index has the largest effect in some high-income countries. An approach achieving reductions in multiple risk factors has the largest impact for almost all regions. Achieving these goals can be accomplished only if countries set priorities, implement cost-effective population wide strategies, and collaborate in public-private partnerships across multiple sectors., (© 2016 American Heart Association, Inc.)
- Published
- 2016
- Full Text
- View/download PDF
13. Vancouver Transcatheter Aortic Valve Replacement Clinical Pathway: Minimalist Approach, Standardized Care, and Discharge Criteria to Reduce Length of Stay.
- Author
-
Lauck SB, Wood DA, Baumbusch J, Kwon JY, Stub D, Achtem L, Blanke P, Boone RH, Cheung A, Dvir D, Gibson JA, Lee B, Leipsic J, Moss R, Perlman G, Polderman J, Ramanathan K, Ye J, and Webb JG
- Subjects
- Aortic Valve physiopathology, Aortic Valve Stenosis diagnosis, Aortic Valve Stenosis mortality, Aortic Valve Stenosis physiopathology, British Columbia, Diffusion of Innovation, Heart Valve Prosthesis, Humans, Models, Organizational, Patient Safety, Postoperative Complications etiology, Postoperative Complications therapy, Program Evaluation, Risk Factors, Time Factors, Transcatheter Aortic Valve Replacement adverse effects, Transcatheter Aortic Valve Replacement instrumentation, Transcatheter Aortic Valve Replacement mortality, Treatment Outcome, Aortic Valve surgery, Aortic Valve Stenosis surgery, Critical Pathways organization & administration, Delivery of Health Care, Integrated organization & administration, Length of Stay, Patient Discharge, Process Assessment, Health Care organization & administration
- Abstract
We describe the development, implementation, and evaluation of a standardized clinical pathway to facilitate safe discharge home at the earliest time after transfemoral transcatheter aortic valve replacement. Between May 2012 and October 2014, the Heart Team developed a clinical pathway suited to the unique requirements of transfemoral transcatheter aortic valve replacement in contemporary practice. The components included risk-stratified minimalist periprocedure approach, standardized postprocedure care with early mobilization and reconditioning, and criteria-driven discharge home. Our aim was to reduce variation in care, identify a subgroup of patients suitable for early discharge (≤48 hours), and decrease length of stay for all patients. We addressed barriers related to historical practices, complex multidisciplinary stakeholder engagement, and adoption of length of stay as a quality indicator. We retrospectively reviewed the experiences of 393 consecutive patients; 150 (38.2%) were discharged early. At baseline, early discharge patients had experienced less previous balloon aortic valvuloplasty, had higher left ventricular ejection fraction, better cognitive function, and were less frail than the standard discharge group (>48 hours). Early discharge was associated with the use of local anesthesia, implantation of balloon expandable device, avoidance of urinary catheter, and early removal of temporary pacemaker. Median length of stay was 1 day for early discharge and 3 days for other patients; 97.7% were discharged home. There were no differences in 30-day mortality (1.3%), disabling stroke (0.8%), or readmission (10.7%). The implementation of a transcatheter aortic valve replacement clinical pathway shifted the program's approach to combine standardized processes and individual risk stratification. The Vancouver transcatheter aortic valve replacement clinical pathway requires a rigorous assessment to determine its efficacy, safety, and reproducibility., (© 2016 American Heart Association, Inc.)
- Published
- 2016
- Full Text
- View/download PDF
14. Transition to palliative care when transcatheter aortic valve implantation is not an option: opportunities and recommendations.
- Author
-
Lauck SB, Gibson JA, Baumbusch J, Carroll SL, Achtem L, Kimel G, Nordquist C, Cheung A, Boone RH, Ye J, Wood DA, and Webb JG
- Subjects
- Aortic Valve Stenosis surgery, Communication, Humans, Medical Futility, Risk Factors, Severity of Illness Index, Transcatheter Aortic Valve Replacement methods, Aortic Valve Stenosis psychology, Palliative Care organization & administration, Palliative Care psychology, Quality of Life
- Abstract
Purpose of Review: Transcatheter aortic valve implantation (TAVI) is the recommended treatment for most patients with symptomatic aortic stenosis at high surgical risk. However, TAVI may be clinically futile for patients who have multiple comorbidities and excessive frailty. This group benefits from transition to palliative care to maximize quality of life, improve symptoms, and ensure continuity of health services. We discuss the clinical determination of utility and futility, explore the current evidence guiding the integration of palliative care in procedure-focused cardiac programs, and outline recommendations for TAVI programs., Recent Findings: The determination of futility of treatment in elderly patients with aortic stenosis is challenging. There is a paucity of research available to guide best practices when TAVI is not an option. Opportunities exist to build on the evidence gained in the management of end of life and heart failure. TAVI programs and primary care providers can facilitate improved communication and processes of care to provide decision support and transition to palliative care., Summary: The increased availability of transcatheter options for the management of valvular heart disease will increase the assessment of people with life-limiting conditions for whom treatment may not be an option. It is pivotal to bridge cardiac innovation and palliation to optimize patient outcomes.
- Published
- 2016
- Full Text
- View/download PDF
15. Coronary obstruction in transcatheter aortic valve-in-valve implantation: preprocedural evaluation, device selection, protection, and treatment.
- Author
-
Dvir D, Leipsic J, Blanke P, Ribeiro HB, Kornowski R, Pichard A, Rodés-Cabau J, Wood DA, Stub D, Ben-Dor I, Maluenda G, Makkar RR, and Webb JG
- Subjects
- Coronary Occlusion etiology, Coronary Occlusion prevention & control, Endoscopy, Humans, Postoperative Complications prevention & control, Preoperative Care, Reoperation, Risk, Coronary Occlusion diagnosis, Postoperative Complications diagnosis, Transcatheter Aortic Valve Replacement
- Published
- 2015
- Full Text
- View/download PDF
16. Moving from political declaration to action on reducing the global burden of cardiovascular diseases: a statement from the global cardiovascular disease taskforce.
- Author
-
Smith SC Jr, Chen D, Collins A, Harold JG, Jessup M, Josephson S, Logstrup S, Jur C, Sacco RL, Vardas PE, Wood DA, and Zoghbi WA
- Subjects
- Cardiovascular Diseases diagnosis, Cardiovascular Diseases therapy, Humans, United Nations trends, Advisory Committees trends, Cardiovascular Diseases epidemiology, Global Health trends, World Health Organization
- Published
- 2013
- Full Text
- View/download PDF
17. Anatomical and procedural features associated with aortic root rupture during balloon-expandable transcatheter aortic valve replacement.
- Author
-
Barbanti M, Yang TH, Rodès Cabau J, Tamburino C, Wood DA, Jilaihawi H, Blanke P, Makkar RR, Latib A, Colombo A, Tarantini G, Raju R, Binder RK, Nguyen G, Freeman M, Ribeiro HB, Kapadia S, Min J, Feuchtner G, Gurtvich R, Alqoofi F, Pelletier M, Ussia GP, Napodano M, de Brito FS Jr, Kodali S, Norgaard BL, Hansson NC, Pache G, Canovas SJ, Zhang H, Leon MB, Webb JG, and Leipsic J
- Subjects
- Aged, Aged, 80 and over, Aortic Rupture diagnostic imaging, Aortic Rupture epidemiology, Aortic Valve diagnostic imaging, Aortic Valve Stenosis diagnostic imaging, Aortic Valve Stenosis epidemiology, Calcinosis complications, Calcinosis diagnostic imaging, Calcinosis epidemiology, Cohort Studies, Female, Heart Valve Prosthesis Implantation methods, Humans, Logistic Models, Male, Predictive Value of Tests, Risk Factors, Tomography, X-Ray Computed, Angioplasty, Balloon adverse effects, Aortic Rupture etiology, Aortic Valve Stenosis therapy, Cardiac Catheterization, Heart Valve Prosthesis Implantation adverse effects
- Abstract
Background: Aortic root rupture is a major concern with balloon-expandable transcatheter aortic valve replacement (TAVR). We sought to identify predictors of aortic root rupture during balloon-expandable TAVR by using multidetector computed tomography., Methods and Results: Thirty-one consecutive patients who experienced left ventricular outflow tract (LVOT)/annular/aortic contained/noncontained rupture during TAVR were collected from 16 centers. A caliper-matched sample of 31 consecutive patients without annular rupture, who underwent pre-TAVR multidetector computed tomography served as a control group. Multidetector computed tomography assessment included short- and long-axis diameters and cross-sectional area of the sinotubular junction, annulus, and LVOT, and the presence, location, and extent of calcification of the LVOT, as well. There were no significant differences between the 2 groups in any preoperative clinical and echocardiographic variables. Aortic root rupture was identified in 20 patients and periaortic hematoma in 11. Patients with root rupture had a higher degree of subannular/LVOT calcification quantified by the Agatston score (181.2±211.0 versus 22.5±37.6, P<0.001), and a higher frequency of ≥20% annular area oversizing (79.4% versus 29.0%, P<0.001) and balloon postdilatation (22.6% versus 0.0%, P=0.005). In conditional logistic regression analysis for the matched data, moderate/severe LVOT/subannular calcifications (odds ratio, 10.92; 95% confidence interval, 3.23-36.91; P<0.001) and prosthesis oversizing ≥20% (odds ratio, 8.38; 95% confidence interval, 2.67-26.33; P<0.001) were associated with aortic root contained/noncontained rupture., Conclusions: This study demonstrates that LVOT calcification and aggressive annular area oversizing are associated with an increased risk of aortic root rupture during TAVR with balloon-expandable prostheses. Larger studies are warranted to confirm these findings.
- Published
- 2013
- Full Text
- View/download PDF
18. Our time: a call to save preventable death from cardiovascular disease (heart disease and stroke).
- Author
-
Smith SC Jr, Collins A, Ferrari R, Holmes DR Jr, Logstrup S, McGhie DV, Ralston J, Sacco RL, Stam H, Taubert K, Wood DA, and Zoghbi WA
- Subjects
- Cardiovascular Diseases prevention & control, Europe, Global Health trends, Humans, Societies, Medical trends, Stroke prevention & control, Time Factors, United States, American Heart Association, Cardiovascular Diseases mortality, Death, Stroke mortality, World Health Organization
- Published
- 2012
- Full Text
- View/download PDF
19. Mechanisms of myocardial infarction in women without angiographically obstructive coronary artery disease.
- Author
-
Reynolds HR, Srichai MB, Iqbal SN, Slater JN, Mancini GB, Feit F, Pena-Sing I, Axel L, Attubato MJ, Yatskar L, Kalhorn RT, Wood DA, Lobach IV, and Hochman JS
- Subjects
- Adult, Aged, Coronary Angiography, Coronary Artery Disease complications, Coronary Artery Disease diagnosis, Coronary Vasospasm complications, Coronary Vasospasm diagnosis, Electrocardiography, Embolism complications, Embolism diagnosis, Female, Humans, Magnetic Resonance Imaging, Middle Aged, Plaque, Atherosclerotic complications, Plaque, Atherosclerotic diagnosis, Prospective Studies, Takotsubo Cardiomyopathy complications, Takotsubo Cardiomyopathy diagnosis, Ultrasonography, Interventional, Myocardial Infarction diagnosis, Myocardial Infarction etiology, Myocardial Ischemia complications, Myocardial Ischemia diagnosis
- Abstract
Background: There is no angiographically demonstrable obstructive coronary artery disease (CAD) in a significant minority of patients with myocardial infarction, particularly women. We sought to determine the mechanism(s) of myocardial infarction in this setting using multiple imaging techniques., Methods and Results: Women with myocardial infarction were enrolled prospectively, before angiography, if possible. Women with ≥50% angiographic stenosis or use of vasospastic agents were excluded. Intravascular ultrasound was performed during angiography; cardiac magnetic resonance imaging was performed within 1 week. Fifty women (age, 57±13 years) had median peak troponin of 1.60 ng/mL; 11 had ST-segment elevation. Median diameter stenosis of the worst lesion was 20% by angiography; 15 patients (30%) had normal angiograms. Plaque disruption was observed in 16 of 42 patients (38%) undergoing intravascular ultrasound. There were abnormal myocardial cardiac magnetic resonance imaging findings in 26 of 44 patients (59%) undergoing cardiac magnetic resonance imaging, late gadolinium enhancement (LGE) in 17 patients, and T2 signal hyperintensity indicating edema in 9 additional patients. The most common LGE pattern was ischemic (transmural/subendocardial). Nonischemic LGE patterns (midmyocardial/subepicardial) were also observed. Although LGE was infrequent with plaque disruption, T2 signal hyperintensity was common with plaque disruption., Conclusions: Plaque rupture and ulceration are common in women with myocardial infarction without angiographically demonstrable obstructive coronary artery disease. In addition, LGE is common in this cohort of women, with an ischemic pattern of injury most evident. Vasospasm and embolism are possible mechanisms of ischemic LGE without plaque disruption. Intravascular ultrasound and cardiac magnetic resonance imaging provide complementary mechanistic insights into female myocardial infarction patients without obstructive coronary artery disease and may be useful in identifying potential causes and therapies. Clinical Trial Registration- URL: http://www.clinicaltrials.gov. Unique identifier: NCT00798122.
- Published
- 2011
- Full Text
- View/download PDF
20. Transcatheter valve-in-valve implantation for failed bioprosthetic heart valves.
- Author
-
Webb JG, Wood DA, Ye J, Gurvitch R, Masson JB, Rodés-Cabau J, Osten M, Horlick E, Wendler O, Dumont E, Carere RG, Wijesinghe N, Nietlispach F, Johnson M, Thompson CR, Moss R, Leipsic J, Munt B, Lichtenstein SV, and Cheung A
- Subjects
- Adult, Aged, Aged, 80 and over, Comorbidity, Fluoroscopy, Follow-Up Studies, Heart Valve Prosthesis Implantation mortality, Humans, Middle Aged, Mitral Valve Insufficiency diagnostic imaging, Mitral Valve Insufficiency mortality, Postoperative Complications mortality, Prosthesis Design, Pulmonary Valve Insufficiency diagnostic imaging, Pulmonary Valve Insufficiency mortality, Pulmonary Valve Insufficiency surgery, Risk Factors, Tricuspid Valve Insufficiency diagnostic imaging, Tricuspid Valve Insufficiency mortality, Tricuspid Valve Insufficiency surgery, Heart Valve Prosthesis, Heart Valve Prosthesis Implantation methods, Mitral Valve Insufficiency surgery, Postoperative Complications surgery, Prosthesis Failure, Reoperation mortality
- Abstract
Background: The majority of prosthetic heart valves currently implanted are tissue valves that can be expected to degenerate with time and eventually fail. Repeat cardiac surgery to replace these valves is associated with significant morbidity and mortality. Transcatheter heart valve implantation within a failed bioprosthesis, a "valve-in-valve" procedure, may offer a less invasive alternative., Methods and Results: Valve-in-valve implantations were performed in 24 high-risk patients. Failed valves were aortic (n=10), mitral (n=7), pulmonary (n=6), or tricuspid (n=1) bioprostheses. Implantation was successful with immediate restoration of satisfactory valve function in all but 1 patient. No patient had more than mild regurgitation after implantation. No patients died during the procedure. Thirty-day mortality was 4.2%. Mortality was related primarily to learning-curve issues early in this high-risk experience. At baseline, 88% of patients were in New York Heart Association functional class III or IV; at the last follow-up, 88% of patients were in class I or II. At a median follow-up of 135 days (interquartile range, 46 to 254 days) and a maximum follow-up of 1045 days, 91.7% of patients remained alive with satisfactory valve function., Conclusions: Transcatheter valve-in-valve implantation is a reproducible option for the management of bioprosthetic valve failure. Aortic, pulmonary, mitral, and tricuspid tissue valves were amenable to this approach. This finding may have important implications with regard to valve replacement in high-risk patients.
- Published
- 2010
- Full Text
- View/download PDF
21. Evaluation of a cardiac prevention and rehabilitation programme for all patients at first presentation with coronary artery disease.
- Author
-
Fox KF, Wood DA, Wright M, Bond S, Nuttall M, Arora B, Dawson E, Devane P, Sutcliffe SJ, and Brown K
- Subjects
- Body Mass Index, Cholesterol, HDL blood, Cholesterol, LDL blood, Humans, Hyperlipidemias drug therapy, Hypolipidemic Agents administration & dosage, Platelet Aggregation Inhibitors administration & dosage, Smoking Cessation statistics & numerical data, United Kingdom, Coronary Disease prevention & control, Coronary Disease rehabilitation, Outcome Assessment, Health Care, Program Evaluation
- Abstract
Background: A cardiac prevention and rehabilitation (CP&R) programme was established for patients following their first clinical episode of coronary heart disease and 1-year outcomes were evaluated against British targets for coronary prevention., Methods: Patients were evaluated 1 year after participation and outcomes compared with patients in the same health district registered with a random half of general practitioners not eligible for the programme (internal reference group) and patients identified in other English centres which participated in the EUROASPIRE II survey (external reference group)., Results: Three hundred and eighteen patients (76% of 417 incident cases) attended for 1-year screening. Of those who participated in the programme 96/113 (85%) attended (Group 1); 152/194 (78%) attended from all those eligible for the programme (Group 2); 166/223 (74%) attended from those receiving usual care in the same health district (Group 3 - internal reference group). In the EUROASPIRE II survey (Group 4 - external reference group) 362/744 (58%) patients were screened. Current smoking at follow-up was Group 1, 8%, Group 2, 11%, Group 3, 13% and Group 4, 18%. Proportions with a BMI < 25 kg/m were 29%, 25%, 32%, 18%; BP < 140/90 mmHg 58%, 56%, 49%, 48%; total cholesterol < 5.0 mmol/l 60%, 54%, 43%, 46%; antiplatelet therapy 88%, 87%, 86%, 81%; beta-blocker therapy 48%, 46%, 46%, 44%; and lipid lowering therapy 56%, 51%, 36%, 69% respectively., Conclusions: A CP&R programme was associated with a majority of coronary patients, whether attending the programme or not, achieving the Joint British Society's recommended prevention targets within the same health district. Specifically, a higher proportion of programme patients reached the cholesterol target of <5.0 mmol/l compared with both usual care and other centres elsewhere. This was achieved by using more lipid lowering therapy compared with usual care in the same health district, but less than other centres outside the health district. The overall results for the whole health district show a higher standard of preventive care compared with contemporary EUROASPIRE II results from other health districts in England.
- Published
- 2002
- Full Text
- View/download PDF
22. Leisure-time physical activity and coronary risk factors in women.
- Author
-
Ashton WD, Nanchahal K, and Wood DA
- Subjects
- Adult, Biomarkers blood, Coronary Disease blood, Cross-Sectional Studies, Female, Humans, Linear Models, Logistic Models, Middle Aged, Physical Fitness, Predictive Value of Tests, Risk Factors, Coronary Disease etiology, Coronary Disease prevention & control, Exercise, Leisure Activities
- Abstract
Background: Evidence that physical activity is cardioprotective in women is not as strong as that observed in men. Furthermore, the extent to which exercise protects against coronary heart disease via its influence on classical risk factors remains unclear. This study examines the relationship between reported physical activity, a range of coronary heart disease risk factors and a 10-year predicted coronary heart disease risk score., Methods: A cross-sectional study of 14,077 female employees aged 30-64 years who were screened between 1988 and 1991 was employed. Measurements included systolic and diastolic blood pressure, body mass index, serum total cholesterol, high-density lipoprotein cholesterol, total cholesterol:high-density lipoprotein cholesterol ratio, low-density lipoprotein cholesterol, triglycerides, apolipoprotein A1, apolipoprotein B, lipoprotein a and fasting blood glucose. Participants were divided into three groups according to reported average frequency of vigorous leisure-time physical activity, that is zero, one to two, or three or more episodes per week., Results: Increasing activity frequency was associated with lower systolic and diastolic blood pressure, total cholesterol, total cholesterol:high-density lipoprotein cholesterol ratio, triglycerides and body mass index (all P < 0.001), low-density lipoprotein cholesterol (P = 0.003), apolipoprotein B (P = 0.04) and blood glucose (P = 0.01) and higher high-density lipoprotein cholesterol (P < 0.001) and apolipoprotein A1 (P = 0.03). There was no association with lipoprotein a. After controlling for possible confounders, these relationships remained statistically significant except for apolipoprotein B and glucose. The odds ratios for being in the top quintile of predicted 10-year coronary heart disease risk for individuals in each category of activity were 1.0 (inactive), 0.70 (one to two episodes of activity per week) and 0.77 (three or more episodes of activity per week)., Conclusion: Women engaging in vigorous, leisure-time physical activity have a less atherogenic coronary heart disease risk factor profile than those who do not, which translates into a potential reduction of approximately 30% in coronary heart disease risk.
- Published
- 2000
- Full Text
- View/download PDF
23. Women married to men with myocardial infarction are at increased risk of coronary heart disease.
- Author
-
Wood DA, Roberts TL, and Campbell M
- Subjects
- Adult, Age Distribution, Case-Control Studies, Family Health, Female, Humans, Incidence, Life Style, Logistic Models, Male, Middle Aged, Prevalence, Risk Factors, Smoking epidemiology, Coronary Disease epidemiology, Myocardial Infarction epidemiology, Spouses
- Abstract
Aim: To measure the prevalence of coronary heart disease (CHD) risk factors in the female partners of men with acute myocardial infarction (AMI)., Method: Consecutive incident cases of men under 65 years of age with AMI surviving to 3 months, their female partners and female healthy controls matched for age and marital status drawn from the general population were investigated., Results: One-hundred and seventeen cases of AMI in men under 65 years of age and 89 female partners were identified; 133 age- and sex-matched controls were examined for CHD risk factors. Cigarette smoking was more common among the younger partners (25-44 years of age) compared with controls. A body mass index > 28 kg/m2, systolic blood pressure > 150 mmHg, diastolic blood pressure > 90 mmHg and cholesterol > 6.5 mmol/l were all significantly more common in partners compared with controls. In a logistic regression of age, smoking habit, blood pressure, cholesterol and body mass index, based on 89 female partners and 132 controls with complete data, body mass index > 28 kg/m2 (odds ratio 2, 17, 95% CI 1.11-4.23) and cholesterol > 6.5 mmol/l (odds ratio 2.21, 95% CI 1.08-4.49) were both significantly more common in the female partners compared with controls., Conclusions: Women married to men with AMI have a higher frequency of CHD risk factors compared with married women in the general population, consistent with a shared family lifestyle putting both adults at higher risk of CHD. Screening blood relatives in families prematurely affected by CHD is widely advocated; such screening should include partners.
- Published
- 1997
- Full Text
- View/download PDF
24. Using a coronary risk score for screening and intervention in general practice. British Family Heart Study.
- Author
-
Thompson SG, Pyke SD, and Wood DA
- Subjects
- Adult, Age Factors, Blood Pressure, Cholesterol blood, Female, Humans, Male, Middle Aged, Risk Factors, Smoking epidemiology, Surveys and Questionnaires, Coronary Disease epidemiology, Family Practice, Mass Screening methods
- Abstract
Aim: To investigate whether a risk score proposed by the British Regional Heart Study (BRHS), derived from data collected in 1978-1980, provides an appropriate basis for current coronary risk factor screening and intervention in general practice., Methods: The BRHS risk score was applied to 1993 men aged 40-59 years and 1353 women aged 35-59 years, from 13 general practices in England, Wales and Scotland, who had health checks during 1991-1992 in the British Family Heart Study (FHS). Modifications to the BRHS risk score were made in order to identify subjects with a current high risk compared with others of the same age and sex. These were validated on 3272 men and 2229 women recruited from different general practices during 1992-1994 in the FHS., Results: Only 9% of men in the FHS fell into the published top (highest risk) quintile of the BRHS score, versus an expected 20%, and 44% fell into the bottom quintile. Scores were, on average, substantially lower in the FHS men than in the BRHS men, principally because of lower measured cholesterol levels (using a Reflotron) and a lower prevalence of cigarette-smoking. The BRHS scores also tended to increase with age, disproportionately identifying older subjects, and were substantially lower in women than in men. Simple age-related modifications to the risk score were therefore devised to overcome these problems. These modifications performed well in the validation., Conclusions: The substantial difference in risk scores between the BRHS and FHS men may reflect both a real reduction in risk and changes in calibration and methodology. Current use of the BRHS risk score may therefore mislead doctors and patients in the direction of complacency. In addition, the published BRHS risk score has an age-dependence that is undesirable in terms of guiding the intensity of lifestyle intervention which should be offered to an individual patient. The simple modifications proposed provide a more appropriate basis for coronary risk factor screening and intervention in general practice, and one that can be used both for men and for women.
- Published
- 1996
25. Objective measurement of normal facial movement with video microscaling.
- Author
-
Wood DA, Hughes GB, Secic M, and Good TL
- Subjects
- Cephalometry, Humans, Reproducibility of Results, Facial Muscles physiology, Movement physiology, Video Recording methods
- Abstract
This study examines variability in facial movements in normal subjects using a new objective method of measuring facial movement, video microscaling. Video microscaling superimposes a computer-generated measuring scale over a video recorded image of facial movements. Distances moved are determined digitally. Eleven subjects were tested raising the eyebrows and smiling five times on two separate days. Test-retest, day-to-day, side-to-side, and intersubject variability were evaluated. Average variability was relatively low; however, some normal subjects exhibited considerable variability, particularly from day-to-day and from side-to-side. Because of this, a facial nerve grading system based solely on objective measurements of facial movements may be invalid. Video microscaling is a promising research technique.
- Published
- 1994
26. Fifty-seven years ago in Anesthesia & Analgesia. D. A. Wood: Survey of anesthesia given in 550 brain operations in the years 1921 to 1930 inclusive. Current Researches in Anesthesia and Analgesia: 1932;11:201-5.
- Author
-
Wood DA
- Subjects
- History, 20th Century, United States, Anesthetics history, Neurosurgery history
- Published
- 1989
27. Bilateral adrenalectomy for advanced carcinoma of the breast with preliminary observations on the effect of the liver on the metabolism of adrenal cortical steroids.
- Author
-
GALANTE M, RUKES JM, FORSHAM PH, WOOD DA, and BELL HG
- Subjects
- Humans, Adrenal Cortex, Adrenal Cortex Hormones, Adrenal Glands surgery, Adrenalectomy, Breast, Breast Neoplasms, Liver physiology
- Published
- 1954
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.